StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)

Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –

TG Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

TG Therapeutics's pe ratio was 24.0× on Nov 11, 2026, against 12.0× a year earlier. Over the last 4 years it ranged from 0.2× to 303.4×, with a median of 19.8×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202624.0×+13.3
2025Dec 31, 202510.7×−30.4
2024Oct 31, 202441.1×+40.4
2012Jan 31, 20120.7×+0.5
2011Dec 30, 20110.2×–

More TG Therapeutics figures

See a number that looks wrong?